This idea is consistent with the finding that ablation of Ptpn11/SHP2 in myeloid cells is protective in inflammation-induced colitis, a precancer setting, and in transformation to colon cancer (Xiao et al, 2018), and consistent with effects described in a diverse set of cancers (Tang et al, 2022; Quintana et al, 2020; Christofides et al, 2023; reviewed in Sodir et al [2023]). Here, PTPN11 is linked to malignant colon neoplasm.